Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,348.04 85.48 0.53%
S&P 500 1,849.82 6.84 0.37%
NASDAQ 4,052.65 18.49 0.46%
Ticker Volume Price Price Delta
STOXX 50 3,123.37 31.85 1.03%
FTSE 100 6,569.08 27.47 0.42%
DAX 9,264.69 90.98 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

AtriCure Announces September Investor Conference Schedule



  AtriCure Announces September Investor Conference Schedule

Business Wire

WEST CHESTER, Ohio -- August 15, 2013

AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in the
development of technologies and solutions for the treatment of atrial
fibrillation, or Afib, and systems for the exclusion of the left atrial
appendage, today announced that it will be participating in two investor
conferences in September.

AtriCure management is scheduled to present at the Stifel 2013 Healthcare
Conference at the Four Seasons Hotel in Boston on Thursday, September 12, 2013
at 9:45 a.m. Eastern Time. A live audio webcast and replay of the presentation
will be available for 30 days following the presentation at www.atricure.com.

AtriCure management is also scheduled to participate in the 6^th Annual
Barrington Research Growth Conference in Chicago on September 4, 2013.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial
fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of atrial fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in patients
undergoing certain open concomitant procedures. AtriCure’s AtriClip Left
Atrial Appendage (LAA) exclusion device is the most widely implanted device
for LAA management worldwide. The company believes cardiothoracic surgeons are
adopting its ablation and LAA management devices for the treatment of Afib and
reduction of Afib related complications such as stroke. Afib affects more than
5.5 million people worldwide.

Contact:

AtriCure, Inc.
Andy Wade, Vice President and Chief Financial Officer, 513-755-4564
awade@atricure.com
OR
Investor Relations Contact
Westwicke Partners
Lynn Pieper, 415-202-5678
lynn.pieper@westwicke.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement